Atsena Therapeutics
Atsena Therapeutics is a clinical-stage gene therapy company focused on developing treatments for inherited retinal diseases. Their clinical programs include therapies for X-linked retinoschisis (XLRS) and GUCY2D-associated Leber congenital amaurosis (LCA1). Atsena utilizes an adeno-associated virus (AAV) technology platform, including a novel spreading capsid (AAV.SPR), to target specific retinal conditions. Their ongoing research aims to prevent blindness caused by genetic mutations and is powered by their innovative approach to ocular gene therapy.
Domain
atsenatx.com
Country
United StatesIndustry
BiotechnologyEmployees
11-50
Last Funding
$150.0M
Founded
2018
Tech Stack (16 technologies)
Frequently Asked Questions
What technologies does Atsena Therapeutics use?+
Atsena Therapeutics uses 16 technologies including Ivory Search, WordPress, CookieYes.
What industry is Atsena Therapeutics in?+
Atsena Therapeutics operates in the Biotechnology industry.
Where is Atsena Therapeutics based?+
Atsena Therapeutics is headquartered in United States.
Explore More
Need this data at scale?
Get ready-to-use datasets: companies, technologies, and tech adoption signals across 3M+ websites.
Browse DatasetsData last updated: June 2026